159 related articles for article (PubMed ID: 27758143)
1. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
2. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
3. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
6. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma.
Hegyi M; Arany A; Semsei AF; Csordas K; Eipel O; Gezsi A; Kutszegi N; Csoka M; Muller J; Erdelyi DJ; Antal P; Szalai C; Kovacs GT
Oncotarget; 2017 Feb; 8(6):9388-9398. PubMed ID: 27566582
[TBL] [Abstract][Full Text] [Related]
8. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
9. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
10. The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.
Lambrecht L; Sleurs C; Labarque V; Dhooge C; Laenen A; Sinnaeve F; Renard M; Uyttebroeck A
Pharmacogenomics; 2017 Jun; 18(8):787-795. PubMed ID: 28592186
[TBL] [Abstract][Full Text] [Related]
11. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
13. Antifolate analogs: mechanism of action, analytical methodology, and clinical efficacy.
Fleisher M
Ther Drug Monit; 1993 Dec; 15(6):521-6. PubMed ID: 8122287
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.
Bodmer N; Walters DK; Fuchs B
Pediatr Blood Cancer; 2008 Apr; 50(4):905-8. PubMed ID: 17534933
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.
Hattinger CM; Casotti C; Patrizio MP; Luppi S; Fantoni L; Scotlandi K; Ibrahim T; Serra M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233089
[TBL] [Abstract][Full Text] [Related]
17. Advances in individual prediction of methotrexate toxicity: a review.
Schmiegelow K
Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
[TBL] [Abstract][Full Text] [Related]
18. Folate during antifolate chemotherapy: what we know... and do not know.
Robien K
Nutr Clin Pract; 2005 Aug; 20(4):411-22. PubMed ID: 16207681
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
20. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]